Your Money
Spanish bank bailout gets go-ahead

Startups will gain from GOP's immigration pain

Knight Capital stock surges on buyout offer from Getco

When to follow the barbarians

The fiscal cliff and private equity

British banks may need more capital

BlackRock's new bond plan

Why 'cheap' stocks aren't always good

Where's the stimulus, Obama?

Eurozone business mood ticks up

Cyber Monday gives eBay a big boost

Goldman Sachs to leave crime scene, exit CSI?

How to really stop (some) insider trading

Why Italian bonds are rallying

Aston Martin at risk of downgrade

Bond investors, beware

U.K. targets Google, Amazon, Starbucks on taxes

BlackRock: There's hidden value in CASSH

Costco's odd fiscal cliff dividend deal

The Fed is backing foreign banks into a corner
строительство домов
Is Obamacare killing medical device startups?
Venture capitalists pumped less money into U.S. medical device companies last quarter than in any similar period since 2004. And Elizabeth MacDonald of Fox Business has identified the culprit: President Obama.

The issue, MacDonald argues, is a new 2.3% excise tax to be paid by medical device companies on gross sales. It's part of the Affordable Care Act (a.k.a. Obamacare), and is expected to generate around $29 billion in revenue over its first decade (beginning on January 1).

Without doubt, this new tax is problematic for medical device companies. And that goes double for startups that want to conserve or reinvest every available dollar, as they strive for profitability. But MacDonald's contention that the excise tax is destroying VC investment in the medical device sector is absurd.

For starters, let's look at the numbers MacDonald cites. Yes, just U.S.-based medical device companies raised just $434 million in Q3 2012, the lowest level since $337 million was disbursed to such companies in Q1 2004. And, yes, it is a major decrease from the $687 million invested in Q2 2012...

Hey, wait a minute: There was $687 million invested in Q2 2012? Were the venture capitalists unaware of the coming excise tax? You know, the one that became law two years earlier? Don't VCs expect to be invested in their companies for up to ten years? Or how about the $705 million invested in Q1 2012, which was significantly higher than the $518 million invested in Q4 2011? In fact, medical device companies raised more VC funding in 2011 than in either 2009 or 2010.

MacDonald provides a link to some of this data, but doesn't bother to mention it in her own column. Instead, she quotes Allison Giles, who is identified as "a top executive at Cook Medical, the world's largest privately owned medical-device company." Giles, conveniently, claims that the excise tax is the "biggest" reason for the Q3 investment drop.

A few things readers might want to know about Ms. Giles. First, she is Cook Medical's VP of federal affairs. Second, she used to work on Capitol Hill as lobbyist and, before that, as a Republican staffer. Third, Cook Group has never actually received venture capital funding, nor does it appear to have invested in any startups.

So I called Giles, to ask why she thinks the excise tax is primarily to blame for the Q3 investment drop. First she said she'd be happy to speak with me. Then she said that she'd have to check with what her PR people told MacDonald, while simultaneously acknowledging that she also spoke to McDonald herself. Finally, she said she was distracted by an email and would get right back to me. Then I got a call back from Cook Group communications rep, who said Giles isn't available until next week.

For what it's worth, I also rang up some actual venture capitalists about the state of medical device investing. They all told me the same thing: The excise tax is clearly an unwelcome burden, but hardly a driving factor in investment decisions. Instead, more salient issues are an increasingly-treacherous FDA approval requirement for medical devices and a relatively lackluster exit environment.

"Devices have become hard to make money in," says Terry McGuire, a co-founder of Polaris Venture Partners and former chairman of the National Venture Capital Association. "Not only because they cost more due to the FDA process, but also because you can't get as much money when you sell them as you can get for a pharma company."

Medical device startups are facing a number of headwinds when it comes to securing venture capital. There's no need to exaggerate the weaker ones to score political points.

Для печати

Why aren't big banks issuing more long-term debt?

Alan Simpson paints dire market outlook

Discount lobster not a hit with diners, or investors

Special dividends: Big waste of cash for tech

Banks book record profits off Fannie and Freddie

Investing: Where to make money in 2013

Municipal bonds: A train wreck waiting to happen

The defunct startup that beat Best Buy in court

EU slaps record $1.9B fine on cartel

Citigroup to slash 11,000 jobs

Jack Bogle: Vanguard's $2.2 trillion man

ECB sees gloomy 2013, but holds rates

Why you're right to be obsessed with Apple stock

Citigroup layoffs may not go far enough

Marc Lasry: I'm in cash because of cliff

We are working too hard

Is Obamacare killing medical device startups?

Don't believe the hype about special dividends

Aston Martin gets new Italian backer

Netflix CEO Hastings deserves SEC scrutiny